Registrations open for SOSV’s First Sustainable Industry Tech Matchup. Learn More.

More info at the IndieBio website

We have shown in people that our technology expands and activates gamma delta T cells, up to 10,000x better than other known approaches. This profound and durable effect can be harnessed as a monotherapy, or in combination with bispecific T cell engagers (BiTEs). We are at the seed stage with human clinical data to support our approach, significant IP protection, and traction with pharma partners to generate early clinical validation with their bispecific antibodies.